Probiotic Intervention for Gut Function

November 15, 2023 updated by: Probi AB

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Effect of Probiotics on Gut Function in Healthy Chinese Adults

The effect of probiotics on gut function in healthy subjects.

Study Overview

Status

Recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Shanghai, China
        • Recruiting
        • Shanghai 9th People's Hospital
        • Contact:
          • Xiangjun Meng, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age between 18 and 65 years
  • BMI between 18.5 and 27.9 kg/m²
  • Subjects having ≥ 3 bowel movements per day
  • Subject not satisfied with their bowel habits
  • Subject having frequent stools during more than 4 weeks
  • For women: Non menopausal with the same reliable contraception since at least 3 cycles before the beginning of the study and agreeing to keep it during the entire duration of the study
  • Subjects agreeing to keep their dietary and life habits unchanged throughout the study
  • Good general and mental health within the opinion of the investigator
  • Able and willing to participate to the study by complying with the protocol procedures as evidenced by a dated and signed ICF

Exclusion Criteria:

  • Suffering IBS according to Rome IV criteria, chronic intestinal disease, immunodeficiency disorder or immunosuppressive treatment
  • Clinically significant frequent constipation or diarrhea at the screening visit as judged by the Investigator
  • Suffering from a severe chronic disease or GI disorders found to be inconsistent with the conduct of the study by the investigator
  • Intake of antibiotics within 8 weeks prior to the start of the study
  • With regular intake of probiotics within four weeks prior to V1 visit
  • Under treatment or dietary supplement which could significantly affect parameter(s) followed during the study according to the investigator or stopped in a too short period before the V1 visit
  • Suspected alcohol or substance abuse
  • Use of medications other than contraceptives or prescribed medication after consulting with the investigator
  • History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk if participating in the study, or influence the results or the subject´s ability to participate in the study
  • With a known gluten intolerance, milk protein allergy
  • With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredients
  • Pregnant or lactating women or intending to become pregnant within 3 months ahead
  • With significant change in food habits or in physical activity in the 3 months before the V1 visit
  • With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator
  • Having a lifestyle deemed incompatible with the study according to the investigator
  • Currently participating in another clinical study, has done so in the past 30 days or being in the exclusion period of a previous clinical trial
  • Under legal protection (guardianship, wardship) or deprived from his/her rights following administrative or judicial decision
  • Presenting a psychological or linguistic incapability to sign the informed consent or Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements
  • Impossible to contact in case of emergency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Probiotics
Two capsules per day for 8 weeks
Capsule
Placebo Comparator: Placebo
Two capsules per day for 8 weeks
Capsule

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bowel movements
Time Frame: 8 weeks
Reduction of the number of bowel movements
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Xiangjun Meng, MD, Shanghai 9th People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 8, 2023

Primary Completion (Estimated)

August 1, 2024

Study Completion (Estimated)

August 1, 2024

Study Registration Dates

First Submitted

November 30, 2021

First Submitted That Met QC Criteria

November 30, 2021

First Posted (Actual)

December 13, 2021

Study Record Updates

Last Update Posted (Estimated)

November 16, 2023

Last Update Submitted That Met QC Criteria

November 15, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • PEC19132

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gut Function

Clinical Trials on Probiotics

3
Subscribe